Foundayo vs the Wegovy Pill: Comparing the Two Oral GLP-1 Options

A neutral, side-by-side look at two once-daily GLP-1 pills, how they differ in daily routine, what their separate trials showed, and how much each one costs.

For years, if you wanted a GLP-1 medication for weight, the answer was a weekly shot. That is no longer the only path. Two once-daily pills are now approved within a few months of each other, and if you have been reading about Foundayo and the oral Wegovy pill and cannot quite tell them apart, you are in good company. They sound similar. They are both taken by mouth, once a day, for the same goal. But they are different molecules, from different makers, with one meaningful difference in how they fit into an ordinary day. Here is a straight, side-by-side look, with no thumb on the scale for either one.

Two approved pills, two different molecules

Foundayo is the brand name for orforglipron, made by Eli Lilly. It is a once-daily small-molecule (nonpeptide) oral GLP-1 receptor agonist, and the FDA approved it on April 1, 2026 for adults with obesity, or overweight with at least one weight-related condition, used alongside a reduced-calorie diet and more physical activity. It also happened to be the first new molecular entity cleared under the FDA's Commissioner's National Priority Voucher pilot, roughly 50 days after filing, which is unusually fast. If you want the full picture of that one drug, the orforglipron (Foundayo) explainer goes deeper.

The oral Wegovy pill is Novo Nordisk's oral semaglutide 25 mg. Its FDA approval was announced on December 22, 2025, with a U.S. launch in early January 2026, and it was the first oral GLP-1 receptor agonist approved for weight management. Its approved uses include reducing excess body weight and helping keep it off over time, as well as reducing the risk of major cardiovascular events. The oral semaglutide (Wegovy pill) explainer covers that drug on its own. One quick, important note: both of these are brand-name, FDA-approved medications. That is a different category from compounded semaglutide or tirzepatide, which is a distinction we will come back to.

The part that actually changes your day: how you take them

If there is one clear, well-documented difference between these two pills, it is not a marketing point. It is the daily routine. This is worth understanding before anything else, because it is the thing you would live with every single morning.

Foundayo (orforglipron) is taken once a day, at any time of day, with or without food, and with no water restriction. You do not have to plan your day around it. It comes in several tablet strengths, and your prescriber decides which one is right for you and when to adjust, so we will not put dosing instructions here.

The oral Wegovy pill (oral semaglutide) asks more of you. It has to be taken on an empty stomach with no more than a small sip of plain water, up to about 4 ounces or 120 milliliters. Then you wait about 30 minutes before you eat, drink anything else, or take other oral medicines. Taking it with food or extra fluid reduces how much of the drug your body absorbs, so the fasting window is not optional. For some people that is a minor habit, no harder than remembering a thyroid pill. For others, especially anyone who takes several morning medications or who is not a fan of waiting before coffee, it is a real adherence hurdle worth being honest about with yourself.

Neither routine is right or wrong. It is genuinely a personal fit question. If you are weighing a pill against the weekly shot you may already know, our piece on switching from an injection to a pill walks through the trade-offs of that move too.

What the trials showed, and why you cannot stack them side by side

This is where it is easy to be misled, including by well-meaning summaries, so read this part slowly. Both drugs have published trial results. Those results come from different studies, with different designs and different ways of measuring, and there has been no head-to-head trial putting these two pills against each other. That means you cannot fairly say one produces more weight loss than the other. Anyone who tells you otherwise is stretching the data.

For Foundayo, the relevant study is ATTAIN-1. Participants on the highest orforglipron dose lost about 12.4% of their body weight, roughly 27.3 pounds, versus about 0.9% with placebo, under one way of measuring the effect. A second measure, which accounts for people who stopped or changed treatment, showed about 11.1%, roughly 25 pounds, versus 2.1% for placebo.

For the oral Wegovy pill, the relevant study is OASIS 4. Oral semaglutide 25 mg produced a mean weight loss of about 16.6%, with roughly one in three participants losing 20% or more. One caveat matters here: that 16.6% figure reflects the result when people stayed on treatment as intended, not a simple average across everyone who enrolled. Novo Nordisk has described the effect as similar to injectable Wegovy 2.4 mg.

So you have numbers in the same general neighborhood, from two separate experiments. The honest read is that both are meaningful, both are real, and lining them up as if they were the same test would be a mistake. Whichever one a person ends up on, individual results vary quite a bit.

Safety: what both pills ask you to know

The two pills share a family of side effects, because they are both GLP-1 medications. The most common issues are gastrointestinal: nausea, vomiting, and diarrhea, which for many people ease over time as the body adjusts. The oral Wegovy pill also carries a boxed warning, the FDA's most prominent safety notice, for a risk of thyroid C-cell tumors, and it is not for people with a personal or family history of medullary thyroid cancer or a syndrome called MEN 2. Any GLP-1 comes with a list of conditions where it is not appropriate, which is exactly why these are prescription medications and not something to sort out on your own.

A GLP-1 is a treatment for obesity, not a shortcut and not a fix for an unrelated condition. And none of this replaces a conversation with a clinician who knows your history. Do not start, stop, or change any prescription based on a blog post, including this one.

Cost and access in 2026

Prices for both are moving targets, so treat these as approximate manufacturer-listed figures that vary by dose, coverage, and pharmacy, and that change over time.

• Foundayo (orforglipron), from Eli Lilly: self-pay pricing through LillyDirect is tiered by dose, roughly $149 at the lowest strength up to about $349 at the highest. With commercial insurance it can run around $25 per month.
• Oral Wegovy pill (oral semaglutide), from Novo Nordisk: self-pay pricing starts around $149 per month for lower doses and about $299 per month for the higher doses.

There is also a shared access route worth naming. Starting July 1, 2026, some eligible Medicare Part D patients may pay about $50 per month, through a temporary federal Medicare GLP-1 program that covers both of these medications. If cost is your deciding factor, the current numbers from each manufacturer, plus your own coverage, will tell you more than any general figure here.

So who might prefer which?

There is no winner in this comparison, and you should be wary of anyone who declares one. There are only different fits. A few honest generalizations:

• Someone who wants the simplest possible routine, no fasting window and no timing rules, often leans toward the flexibility of Foundayo.
• Someone who is comfortable taking a morning pill on an empty stomach, and who wants a medication with a longer real-world track record as a molecule, may be drawn to the oral Wegovy pill.
• Cost, insurance, other medications, medical history, and how your body tolerates a GLP-1 will often matter more than any headline trial number.

If you are still deciding whether to act now or hold out for something else, our take on whether it is worth waiting for GLP-1 pills may help you think it through.

Where a clinic like New Hope Weight Loss fits

To be clear and fair: New Hope Weight Loss does not dispense Foundayo or the branded Wegovy pill, and no clinic can compound a copy of an FDA-approved drug. What we provide is physician-supervised care with compounded semaglutide and tirzepatide, which are prepared by licensed U.S. pharmacies and are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality. That is a different product category from the two branded pills discussed above, and we would rather say so plainly than blur the line.

What a visit gives you is a real evaluation. After a one-time $119 medical review, Dr. Anjmun Sharma can help you weigh your actual options, including telling you when a branded oral medication like one of these is the better choice for you. Eligibility and results vary from person to person, and the only way to know what fits is to talk it through with a clinician. Neither Eli Lilly nor Novo Nordisk is affiliated with our clinic, and naming their products here is simply so you can compare them honestly.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.